Alaunos Therapeutics (TCRT) AI Stock Analysis

• Market Cap: $7.90M
• Dividend Yield: N/A
• Average Volume (3M): 860.99K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.28
• Revenue Growth: N/A
• EPS Growth: 68.59%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 2,231,829
• 10 Day Avg. Volume: 2,529,145
• 30 Day Avg. Volume: 860,987
• PEG Ratio: <0.01
• Price to Book (P/B): 1.48
• Price to Sales (P/S): 305.84
• P/FCF Ratio: -0.62
• Enterprise Value/Market Cap: 0.44
• Enterprise Value/Revenue: 578.84
• Enterprise Value/Gross Profit: -19.40
• Enterprise Value/Ebitda: -0.87
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: ―

Alaunos Therapeutics' overall score is primarily impacted by its weak financial performance with ongoing losses and negative cash flows. While the technical analysis shows some positive momentum, the negative P/E ratio and lack of dividends underscore valuation challenges. The absence of earnings call and corporate events information further limits the stock’s appeal.

Positive Factors

Innovative Therapy Platform

Alaunos' proprietary TCR therapy platform harnesses the immune system to target cancer cells, offering a durable competitive advantage in oncology.

No Debt

Alaunos' lack of debt reduces financial risk, providing flexibility to pursue strategic initiatives without the burden of interest obligations.

Board Alignment with Equity

Board's decision to receive equity compensation aligns their interests with shareholders, potentially driving long-term strategic focus and performance.

Negative Factors

Negative Cash Flow

Ongoing negative cash flow indicates operational cash outflows exceed inflows, necessitating external funding and impacting financial sustainability.

Lack of Profitability

Persistent unprofitability and widening losses challenge Alaunos' ability to sustain operations and invest in growth without external capital.

Declining Equity Base

A declining equity base signals potential financial instability, limiting Alaunos' capacity to absorb losses and invest in future growth.

Alaunos Therapeutics Business Overview & Revenue Model

Company Description

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.

How the Company Makes Money

Alaunos Therapeutics generates revenue primarily through the development and commercialization of its TCR-based therapies. The company may earn income through collaboration agreements, research and development partnerships, and potential licensing deals with larger pharmaceutical companies. These partnerships can include milestone payments and royalties based on the successful development and commercialization of therapies. Additionally, Alaunos may seek funding through private and public investments to support ongoing research and clinical trials, although these do not directly constitute revenue.

Alaunos Therapeutics Financial Statement Overview

Summary

Alaunos Therapeutics faces significant financial challenges with continuous losses, negative cash flows, and a declining equity base. While the absence of debt reduces financial risk, the lack of profitability and need for external funding highlight the company's precarious financial position.

Income Statement

Alaunos Therapeutics has struggled with profitability, evidenced by its negative net income and EBIT margins over recent years. Despite a marginal increase in revenue in the latest year, the company remains unprofitable, with widening losses. The gross profit margin is effectively non-existent due to minimal revenue.

Balance Sheet

The company has a relatively strong equity position with no debt, reflected in a debt-to-equity ratio of zero. However, its equity ratio has declined due to shrinking stockholders' equity, which signals potential financial instability. Return on equity is not meaningful due to persistent losses.

Cash Flow

Alaunos Therapeutics reports negative free cash flow, indicating cash outflows from operations continue to exceed cash inflows. Although operating cash flow has improved from previous years, the company still requires substantial external financing to support operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.00K	10.00K	5.00K	2.92M	398.00K	0.00
Gross Profit	-179.00K	10.00K	-4.80M	2.92M	398.00K	-1.13M
EBITDA	-4.01M	-4.68M	-30.90M	-31.82M	-74.97M	-78.85M
Net Income	-4.03M	-4.68M	-35.14M	-37.73M	-78.75M	-79.98M
Balance Sheet
Total Assets	3.72M	2.75M	8.26M	64.94M	94.86M	146.34M
Cash, Cash Equivalents and Short-Term Investments	1.94M	1.09M	6.06M	39.06M	76.05M	115.07M
Total Debt	0.00	0.00	0.00	20.07M	30.09M	4.81M
Total Liabilities	921.00K	692.00K	1.96M	26.38M	36.81M	22.36M
Stockholders Equity	2.80M	2.06M	6.31M	38.55M	58.06M	123.98M
Cash Flow
Free Cash Flow	-3.01M	-4.97M	-30.34M	-29.45M	-64.79M	-66.79M
Operating Cash Flow	-2.91M	-4.97M	-30.14M	-29.23M	-61.47M	-57.01M
Investing Cash Flow	-97.00K	0.00	1.35M	-193.00K	-3.32M	-9.78M
Financing Cash Flow	3.26M	0.00	-18.14M	6.37M	25.78M	102.12M

Alaunos Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.54
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCRT, the sentiment is Positive. The current price of 3.54 is below the 20-day moving average (MA) of 3.66, above the 50-day MA of 3.32, and above the 200-day MA of 3.00, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 51.82 is Neutral, neither overbought nor oversold. The STOCH value of 39.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TCRT.

Alaunos Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CYCN	47 Neutral	$7.58M	-2.54	-24.80%	―	1371.65%	64.13%
TCRT	45 Neutral	$7.90M	-1.53	-145.65%	―	―	68.59%
CLDI	44 Neutral	$8.31M	-0.13	―	―	―	87.42%
GRI	42 Neutral	$2.87M	-0.02	-397.84%	―	―	98.22%
AIM	39 Underperform	$3.79M	-0.07	―	―	-41.05%	57.35%

Alaunos Therapeutics Corporate Events

Alaunos Therapeutics Reaches Settlement With MD Anderson Cancer

On December 17, 2025, Alaunos Therapeutics, Inc. entered into a Settlement and Release Agreement with The University of Texas M.D. Anderson Cancer Center to resolve disputes over unpaid invoices tied to a 2019 research and development agreement. Alaunos agreed to pay a total of $285,055 to MD Anderson in a series of installments running from late December 2025 through May 30, 2026, and both parties granted mutual general releases of claims related to the unpaid invoices, with limited exceptions for breaches of the settlement and certain ongoing matters such as Protocol 2006-0676, effectively closing a financial and legal overhang on their prior collaboration.